His main research concerns Virology, Acquired immunodeficiency syndrome, Immunology, Viral load and Internal medicine. His study in Virology is interdisciplinary in nature, drawing from both Efavirenz, Reverse transcriptase and Drug resistance. His Acquired immunodeficiency syndrome research incorporates themes from Clinical research, MEDLINE and Intensive care medicine.
His Immunology research is multidisciplinary, incorporating elements of Prospective cohort study, Pharmacotherapy, Cohort study and Antiretroviral therapy. His studies in Viral load integrate themes in fields like Viremia, Pain scale and Lentivirus. As part of one scientific family, David Katzenstein deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gastroenterology, and often Chemotherapy.
His scientific interests lie mostly in Virology, Immunology, Acquired immunodeficiency syndrome, Drug resistance and Internal medicine. His work is dedicated to discovering how Virology, Efavirenz are connected with Nevirapine and Reverse-transcriptase inhibitor and other disciplines. His work in Immunology addresses subjects such as Cohort, which are connected to disciplines such as Cohort study.
His Acquired immunodeficiency syndrome study focuses on Sida in particular. His research in Drug resistance intersects with topics in Mutation, HIV drug resistance, Resistance mutation and Genotyping, Genotype. David Katzenstein has included themes like Gastroenterology, Lamivudine, Oncology and Ritonavir in his Internal medicine study.
David Katzenstein mostly deals with Drug resistance, Virology, Internal medicine, Viral load and HIV drug resistance. His Drug resistance study integrates concerns from other disciplines, such as Regimen, Acquired immunodeficiency syndrome, Immunology, Transmission and Genotyping. His Acquired immunodeficiency syndrome research includes themes of Cross-sectional study and Public health.
The study incorporates disciplines such as Mutation, Efavirenz, Resistance mutation, Genotype and Nevirapine in addition to Virology. He has researched Internal medicine in several fields, including Tuberculosis and Abacavir. His Viral load research includes elements of Viral suppression, Virological failure, Lopinavir, Ritonavir and Pediatrics.
David Katzenstein focuses on Virology, Drug resistance, Viral load, Internal medicine and Regimen. He is involved in the study of Virology that focuses on Reverse-transcriptase inhibitor in particular. His studies deal with areas such as Nevirapine, Efavirenz and Transmission as well as Drug resistance.
His studies in Transmission integrate themes in fields like Acquired immunodeficiency syndrome, Sequence analysis, Public health and Random effects model. The various areas that David Katzenstein examines in his Viral load study include Intensive care medicine and Ritonavir. His Internal medicine study integrates concerns from other disciplines, such as Lamivudine and Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel
Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell.
JAMA (2000)
A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
Scott M. Hammer;David A. Katzenstein;Michael D. Hughes;Holly Gundacker.
The New England Journal of Medicine (1996)
Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel
Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner.
JAMA (2006)
Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Patrick G. Yeni;Scott M. Hammer;Charles C. J. Carpenter;David A. Cooper.
JAMA (2002)
Antiretroviral Therapy for HIV Infection in 1997: Updated Recommendations of the International AIDS Society—USA Panel
Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch.
JAMA (1997)
Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society–USA Panel
Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch.
JAMA (1998)
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel
Charles C. J. Carpenter;Margaret A. Fischl;Scott M. Hammer;Martin S. Hirsch.
JAMA (1996)
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag.
JAMA (2004)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
C C Carpenter;M A Fischl;S M Hammer;M S Hirsch.
JAMA (1996)
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
David A. Katzenstein;Scott M. Hammer;Michael D. Hughes;Holly Gundacker.
The New England Journal of Medicine (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Stanford University
Stanford University
Columbia University Medical Center
University of the Witwatersrand
University of Miami
United States Department of Veterans Affairs
Royal Hallamshire Hospital
University of California, San Diego
Sheba Medical Center
University of North Carolina at Chapel Hill
Ben-Gurion University of the Negev
University of Auckland
University of Salento
Nielsen (United States)
University of California, Berkeley
Kyoto University
Stony Brook University
University of Aberdeen
Institut de Physique du Globe de Paris
University of California, Los Angeles
Goddard Space Flight Center
University of Edinburgh
University of New Mexico
Maria Sklodowska-Curie National Research Institute of Oncology
Moffitt Cancer Center
University of Edinburgh